Early toxicity of hypofractionated radiotherapy for prostate cancer.

Background: Hypofractionated accelerated radiotherapy (HART) is now a feasible option for prostate cancer treatment apropos toxicity, biochemical control and shortening of treatment. The aim of this study was to investigate hypofractionated schedules in the treatment of patients with localized prostate cancer.

Patients And Methods: Between 2011-2014, 158 patients were treated using the RapidArc technique with IGRT.